This study is conducted in Europe. The aim of this study is to extract data from the French National Registry holding information about patients having initiated growth hormone therapy with the objective to describe patients receiving growth hormone therapy, assess efficacy and safety of somatropin (Norditropin® SimpleXx®) and evaluate treatment compliance.
Study Type
OBSERVATIONAL
Enrollment
331
Data are extracted from the French National Registry "l'Observatoire National des Prescriptions et Consommations de Médicaments" to where physicians report data about growth hormone treatment
Novo Nordisk Investigational Site
Lyon, France
Weight
Time frame: Once a year for 5 years
Body composition
Time frame: Once a year for 5 years
Waist:Hip Ratio
Time frame: Once a year for 5 years
Body mass index (BMI)
Time frame: Once a year for 5 years
IGF-1 (Insulin-like growth factor 1) concentration
Time frame: Once a year for 5 years
Lipids: Total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglycerides
Time frame: Once a year for 5 years
Dose prescribed
Time frame: Once a year for 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.